Is Tesamorelin legal in Norway?

Tesamorelin is among the peptides readers most often ask about in Norway. This page focuses on the regulatory reality there, not on how to obtain or use it, because that is where reliable, localized information is hardest to find.

In Norway, Tesamorelin has no marketing authorisation. It is FDA-approved in the United States (as Egrifta), but the European marketing-authorisation application was withdrawn in 2012, so there is no authorised tesamorelin product in Norway. It is an unlicensed medicine here.

Because there is no marketing authorisation, Tesamorelin can only be supplied as an unlicensed medicine, via a named-patient or “specials” import that a prescriber requests and takes responsibility for. General or online sale to the public is not lawful, and customs may detain unauthorised shipments. There is no ordinary lawful consumer route in Norway. Any legitimate access runs through the unlicensed-medicine / named-patient framework overseen by DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk).

Selling or supplying Tesamorelin without the required authorisation is an offence in Norway. DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk) sets out the applicable sanctions; we do not reproduce specific figures here because they change. Confirm the current penalties with the regulator. This page reflects our reading of the position as of the last-verified date; regulations change, so confirm with DMP (Norwegian Medical Products Agency, formerly Statens legemiddelverk) before making any decision.